Copper intrauterine device showed no clear difference in observed number of pregnancies (all women) compared with mifepristone (all doses) (low certainty).
Copper intrauterine device may leads to lower any side effect compared with mifepristone (all doses) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Copper intrauterine device may leads to higher specific side effects ‐ lower abdominal pain compared with mifepristone (all doses) (low certainty).
The review found no eligible studies for this question.
Copper intrauterine device may leads to lower menses ‐ delay compared with mifepristone (all doses) (low certainty).
It is very uncertain whether surgical reimplantation of ureters plus antibiotics changes ESKD compared with antibiotics alone (very low certainty).
It is very uncertain whether surgical reimplantation of ureters plus antibiotics changes hypertension compared with antibiotics alone (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether endoscopic injection treatment changes repeat positive urine culture by 1 year compared with antibiotics alone (very low certainty).
It is very uncertain whether endoscopic injection treatment changes microbial resistance to the prophylactic drug compared with antibiotics alone (very low certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).